More Stories

Informist, Friday, May 16, 2025

MUMBAI – New product launches and strong March quarter earnings are expected to help Indian pharma stocks remain in the positive territory in the coming week, analysts at domestic brokerages said. They expect stocks to remain strong as the Indian pharmaceutical companies could be immune to the new executive orders signed by the US President Trump this week to enhance domestic manufacturing. Indian pharmaceutical companies that largely depend on US exports may not get affected as the generics market is competitive, and is expected to not be impacted by Trump's missive.

Trump's Monday order is aimed at bringing the prices for prescription drugs in the US, in line with other developed nations. The executive order institutes the "most-favoured-nation" price model for drugs as a ceiling which means the US will pay for drugs at same levels as the lowest paid by other countries, stated a research report by HDFC Securities. The orders, if implemented, will change the order of global pharmaceutical industry, according to a research report by Nuvama Institutional Equities. Sun Pharma is expected to see some impact as its specialty business accounts for 15-18% of its sales in the US.

Despite uncertainty in the global pharmaceutical market, the Nifty Pharma closed in the positive territory for four days this week and is expected to hold this momentum. The sectoral index's strong performance was backed by Dr. Reddy's Laboratories and Lupin's higher-than-expected quarterly financials. Nifty Pharma ended marginally lower Friday at 21633.20 points, having reached this week's peak on Thursday at 21489.20 points. 

The earnings reports of major pharmaceutical companies, including Zydus Lifesciences, Divis Laboratories and Mankind Pharma, will be in focus for the next week. Granules India, J.B. Chemicals & Pharmaceuticals, and Mankind Pharma were the top three performers on the index this week. 

TOP HEADLINES

* Lupin gets US FDA approval for rivaroxaban tablets
* Alembic Pharma gets US FDA's final approval for Rivaroxaban tablets
* Caplin Point Jan-Mar consol PAT rises 17.3% YoY to INR 1.43 billion
* Earnings Review:Lupin consol Jan-Mar net profit doubles YoY on higher margin
* Mankind Pharma gets INR 3.42 bln additional tax demand from income tax dept
* Piramal Pharma Jan-Mar consol PAT rises nearly 52% YoY to INR 1.54 billion
* JB Chemicals Jan-Mar PAT rises 19% YoY to INR 1.5 billion
* HC directs removal of Chinese co's trademark entry on Mankind Pharma's suit
* Zydus Life gets US FDA establishment inspection report for Ambernath unit
* Caplin Point arm gets US FDA final OK for haloperidol decanoate injection
* Sai Life Sciences Jan-Mar consol PAT up 57% YoY at INR 883 mln, sales up 32%
* Analyst Concall:Cipla sees near-term US revenue run rate around $220 mln/qtr
* Suven Pharma's name, symbol to change on NSE from Monday
* Cipla sees no material impact on business from US executive order on pricing
* Aurobindo Pharma arm CuraTeQ gets UK body nod to market biosimilar Zefylti
* Earnings Review: Cipla's net profit rises 30% on year, beats Street view
* GSK Pharma Jan-Mar PAT rises 34.7% YoY to INR 2.6 billion
* Lupin launches Tolvaptan tablets in US with 180-day drug exclusivity
* Trump signs order to push pharma cos to lower medicine prices in US
* Piramal Pharma to invest $90 mln to expand two facilities in the US
* US FDA tags Piramal Pharma's Turbhe unit as 'voluntary action indicated'
* Trump to sign order to slash drug prices, start most favoured nation policy
* India Ratings assigns 'AA' rating to Eris Lifesciences' bank facilities
* Glenmark Pharma gets US FDA official action indicated tag for Indore unit
* Earnings Review: New pdts, US, Europe help Dr Reddy's sales, PAT beat Street

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

End

Reported by P Madhu Kumar

Edited by Deepshikha Bhardwaj

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2024. All rights reserved.